MEDICAL JOURNAL 25 Discussion No adverse effects of nitrazepam on the haemopoietic system or renal and hepatic function has been noted (Jordan, 1965) . Nor has this drug shown any incompatibility when used with other drugs in the treatment of epilepsy (Kryspin-Exner, 1966) , thyrotoxicosis, cardiac failure, hypertension (Maibach, 1965) , and diabetes mellitus (Wyss and Mader, 1965) . Dependence on, or addiction to, nitrazepam has not been observed (Franke, 1965 ; Bethune et al., 1966) , nor has there been any report of delirium or epileptic seizures on withdrawal of the drug such as may complicate the withdrawal of other hypnotics (Glatt, 1968 (Aitken, 1969) .
The clinical trial clearly showed that nitrazepam was superior to a placebo as a hypnotic drug, and that it was as effective as butobarbitone. There was consistency between the patients' reports on the quality of sleep and the nurses' assessments of the duration of sleep. The results are similar to those of another trial with a similar method of analysis comparing nitrazepam and sodium amylobarbitone in psychiatric patients (Davies and Levine, 1967) .
We conclude that nitrazepam is an effective hypnotic which is safe in overdosage.
We 
Introduction
Growth retardation which occurs in severely affected asthmatic children (Falliers et al., 1963, and Norman, 1965) can be accentuated by the use of corticosteroid drugs (Kerrebijn and De Kroon, 1965 
Materials and Methods
Twelve patients who were attending the asthma clinic at the Hospital for Sick Children, Great Ormond Street, London, and showed growth retardation were studied (see Table) . At the time of H.G.H. assay the heights of eight patients were below the third percentile, those of three were on the third percentile, and that of one on the fifth percentile, while all showed retardation of skeletal maturation. Two of the 12 patients were girls and 10 were boys ; their ages ranged from 7-3 to 16-5 years (mean 12-6 years). All of them were severely asthmatic, but 10 also had had or were suffering from eczema and six from hay-fever. Corticosteroids, in doses of prednisone ranging 12-95 from 5 to 10 mg. a day, had been given to eight of the patients, who were all receiving them at the time of testing. In all but one of these the height was known before corticosteroid therapy was begun; while, of the remaining seven, four already showed severe growth-retardation--that is, were on the third percentile for height-and three moderate growth-retardation. The height percentiles of all eight had fallen after they had been receiving corticosteroids for periods ranging from 3-0 to 7-4 years (mean 4 9 years), and when tested for H.G.H. all had heights which fell on or below the third percentile. Of the remaining four patients who had not been treated with corticosteroids all showed severe growth retardation. The heights were plotted on charts devised by Tanner et ad. (1966) . The Bovril test was performed on the patients according to the method described by Jackson et al. (1968) . Capillary blood specimens were taken before the Bovril was administered and thereafter at 30-minute intervals for two-and-a-half hours, Serum growth hormone was determined by a double-antibody technique (Jackson et at., 1968) .
Results
All the patients had a normal H.G.H. response to Bovril (see Table) compared with normal results (----) reported by Jackson et al. (1968) .
The Chart, which shows the mean serum H.G.H. results (with standard deviations) plotted in comparison with the normal results previously reported by Jackson et al. (1968) , demonstrates that the two curves are similar in contour.
Discussion
The depression of growth which follows corticosteroid therapy in asthmatic children is not necessarily due to lack of H.G.H. Furthermore, our findings confirm the work of Morris et al. (1968a) , who showed (Morris et al., 1968b ) that treatment of their patients with H.G.H. over a period of four to eight months did not increase the rate of growth. Moreover, in those children whose growth is depressed as a result of persistent asthma alone satisfactory secretion of H.G.H. does occur. It has been suggested in another context-that is, African pygmies-that there is, either an abnormality in the H.G.H. molecule ) or a tissue subresponsiveness to H.G.H. . No prima facie case for administering H.G.H. to growth-retarded asthmatic children can therefore be made at present.
